CHRONIC PROSTATITIS COLLABORATIVE CLINICAL RESEARCH STUD

描述（摘自申请人摘要） 慢性非感染性前列腺炎或慢性骨盆疼痛综合征（CPPS） 代表了临床医学中最大的挑战之一。 组成 一系列的症状，这些症状是由 病人和他的医生 这些可能包括会阴和大腿疼痛， 阴茎不适、疼痛、腰痛、刺激性和阻塞性 排尿症状，射精功能障碍，疲劳，和各种其他 投诉 治疗通常导致最小或间歇性的改善， 频繁恶化，越来越多的挫折感，以及广泛使用 资源 在CPPS中，医生和研究人员缺乏清晰的认识， 相关的病理生理学和免疫学，缺乏共识， 构成适当的诊断评价和治疗 管理，并不同意如何最好地量化患者的症状和 从而影响生活质量。 该提案的目标是执行 两个具体项目，以解决目前的知识赤字在南太常委会。 第一个涉及症状指数和 CPPS患者的生活质量影响指数。 多中心性质 该项目将允许创建一个工具， 心理测量可靠有效，但易于理解和完成， 患者 通过统一接受的结果测量，研究人员和 临床医生可以开始说同样的语言， 这种疾病的历史及其对各种治疗方法的反应。 二是判断CPPS是否属于不适当的伤害反应 在没有持续的细菌损伤的情况下。 它将建立信号 调节剂，提供了新的和有效的工具来诊断CPPS， 选择并监测个体患者的治疗效果。 我们将 研究来自流体的生物化学、细胞和分子标记物， 前列腺分泌物的细胞，并将这些参数与 在第一个项目中制定的成果衡量标准。 生物 措施将包括量化的白色血细胞，一氧化氮 前列腺液中的活性和荧光原位杂交， 前列腺液细胞用于个体免疫细胞类型和免疫 细胞激活

DESCRIPTION (Taken from the applicant's Abstract) Chronic non-infectious prostatitis or chronic pelvic pain syndrome (CPPS) represents one of the greatest challenges in clinical medicine. It consists of a constellation of symptoms that are subjectively evaluated by both the patient and his physician. These may include perineal and thigh pain, penile discomfort, orchalgia, lower back pain, irritative and obstructive voiding symptoms, ejaculatory dysfunction, fatigue, and a variety of other complaints. Treatments often lead to minimal or intermittent improvement, frequent exacerbations, increasing frustration, and extensive utilization of resources. In CPPS, physicians and researchers lack a clear understanding of the relevant pathophysiology and immunology, lack consensus on what constitutes the appropriate diagnostic evaluation and therapeutic management, and disagree on how best to quantify patients' symptoms and the resulting quality of life impact. The goal of this proposal is to carry out two specific projects that address current knowledge deficits in CPPS. The first involves the development and validation of a symptom index and a quality of life impact index for men with CPPS. The multi-center nature of the project will allow for the creation of an instrument that is psychometrically reliable and valid yet easily understood and completed by patients. With a uniformly accepted outcome measure, researchers and clinicians can begin speaking the same language when assessing the natural history of this disease and its response to various proposed treatments. The second is to determine whether CPPS is an inappropriate injury response in the absence of ongoing bacterial injury. It will establish signal modulators that provide novel and effective tools to diagnose CPPS and to select and monitor treatment efficacy for individual patients. We will study the biochemical, cellular and molecular markers from the fluid and cells of expressed prostatic secretions and correlate these parameters with the outcomes measures developed in the first project. The biological measures will include quantification of white blood cells, nitric oxide activity in prostatic fluid, and fluorescent in situ hybridization of prostate fluid cells for markers of individual immune cell types and immune cell activation.